Drug Profile

Eloralintide - Eli Lilly and Company

Alternative Names: Amylin agonist LA - Eli Lilly and Company; Amylin agonist long acting - Eli Lilly and Company; LY-3841136

Latest Information Update: 14 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

14 Apr 2025 Eli Lilly and Company plans a phase I trial in Obesity (Monotherapy, Combination Therapy) in USA (SC), in April 2024 (NCT06916065)
08 Apr 2025 Eli Lilly and Company plans a phase I trial for Obesity in Singapore (SC) in April 2024 (NCT06916091)
01 Oct 2024 Eli Lilly and Company plans a phase II trial for Obesity (Combination therapy) in USA (SC) in October 2024 (NCT06603571)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com